Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 5
Results: 21
MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1259, doi. 10.1007/s00262-021-03118-9
- By:
- Publication type:
- Article
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1247, doi. 10.1007/s00262-021-03082-4
- By:
- Publication type:
- Article
The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1233, doi. 10.1007/s00262-021-03080-6
- By:
- Publication type:
- Article
The Crohn's-like lymphoid reaction density: a new artificial intelligence quantified prognostic immune index in colon cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1221, doi. 10.1007/s00262-021-03079-z
- By:
- Publication type:
- Article
Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1199, doi. 10.1007/s00262-021-03071-7
- By:
- Publication type:
- Article
A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1275, doi. 10.1007/s00262-021-03070-8
- By:
- Publication type:
- Article
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1157, doi. 10.1007/s00262-021-03068-2
- By:
- Publication type:
- Article
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1129, doi. 10.1007/s00262-021-03067-3
- By:
- Publication type:
- Article
Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1183, doi. 10.1007/s00262-021-03066-4
- By:
- Publication type:
- Article
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1167, doi. 10.1007/s00262-021-03065-5
- By:
- Publication type:
- Article
Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1139, doi. 10.1007/s00262-021-03064-6
- By:
- Publication type:
- Article
Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1115, doi. 10.1007/s00262-021-03062-8
- By:
- Publication type:
- Article
Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1103, doi. 10.1007/s00262-021-03061-9
- By:
- Publication type:
- Article
Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1063, doi. 10.1007/s00262-021-03060-w
- By:
- Publication type:
- Article
Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1049, doi. 10.1007/s00262-021-03059-3
- By:
- Publication type:
- Article
LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1075, doi. 10.1007/s00262-021-03055-7
- By:
- Publication type:
- Article
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1017, doi. 10.1007/s00262-021-03054-8
- By:
- Publication type:
- Article
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1093, doi. 10.1007/s00262-021-03052-w
- By:
- Publication type:
- Article
Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long term follow-up: implication in the progression of cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1033, doi. 10.1007/s00262-021-03044-w
- By:
- Publication type:
- Article
EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1001, doi. 10.1007/s00262-021-03030-2
- By:
- Publication type:
- Article